OncoGenex Pharmaceuticals Inc. to Webcast Discussion of Clinical Development Program and Second Quarter 2013 Financial Results on August 8, 2013
BOTHELL, WA and VANCOUVER, BC, July 30, 2013 /PRNewswire/ - OncoGenex Pharmaceuticals, Inc. (NASDAQ: OGXI) announced today that the Company's second quarter 2013 financial results will be released on Thursday, August 8, 2013, and that the Company will host a conference call and live webcast at 4:30 p.m. ET that afternoon. Management will provide an overview of clinical development activities and discuss the company's financial results.
To access the webcast, log on to the Investor Relations page of the OncoGenex website at www.oncogenex.com. Alternatively, you may access the live conference call by dialing (877) 606-1416 (U.S. & Canada) or (707) 287-9313 (International). A webcast replay will be available approximately two hours after the call and will be archived on www.oncogenex.com for 90 days.
ABOUT ONCOGENEX
OncoGenex is a biopharmaceutical company committed to the development
and commercialization of new therapies that address treatment
resistance in cancer patients. OncoGenex has a diverse oncology
pipeline, with each product candidate having a distinct mechanism of
action and representing a unique opportunity for cancer drug
development. OncoGenex and Teva Pharmaceutical Industries Ltd. have
entered a global collaboration and license agreement to develop and
commercialize OncoGenex' lead drug candidate, custirsen. Custirsen is
currently in Phase 3 clinical development as a treatment in men with
metastatic castrate-resistant prostate cancer and in patients with
advanced, unresectable non-small cell lung cancer. OGX-427 is in Phase
2 clinical development and OGX-225 is currently in pre-clinical
development. More information is available at www.OncoGenex.com.
SOURCE: OncoGenex Pharmaceuticals, Inc.
SOURCE OncoGenex Pharmaceuticals, Inc.
Hey, check out all the research scientist jobs. Post your resume today!